JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Tax-Exempt Bond Index Fund
VTEB
|
+$2.54B |
| 2 |
Amazon
AMZN
|
+$1.38B |
| 3 |
Vanguard Short-Term Corporate Bond ETF
VCSH
|
+$827M |
| 4 |
Public Service Enterprise Group
PEG
|
+$725M |
| 5 |
Union Pacific
UNP
|
+$721M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$1.49B |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.03B |
| 3 |
McDonald's
MCD
|
+$1.01B |
| 4 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$871M |
| 5 |
Exelon
EXC
|
+$709M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 27.19% |
| 2 | Technology | 14.28% |
| 3 | Healthcare | 12.84% |
| 4 | Financials | 10.61% |
| 5 | Consumer Discretionary | 7.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
6151
Lipocine
LPCN
$16.9M
| $1K | ﹤0.01% |
176
| – | – |
2019 Q1
15 quarters
|
|
|
CYPH
6152
Cypherpunk Technologies Inc
CYPH
$327M
| $1K | ﹤0.01% |
228
-391
| -63% | -$2.62K |
2021 Q4
4 quarters
|
|
6153
Mustang Bio
MBIO
$3.57M
| $1K | ﹤0.01% |
3
-29
| -91% | -$9.9K |
2018 Q2
18 quarters
|
|
|
LITS
6154
Lite Strategy Inc
LITS
$42M
| $1K | ﹤0.01% |
300
+108
| +56% | +$703 |
2018 Q2
18 quarters
|
|
6155
Mistras Group
MG
$658M
| $1K | ﹤0.01% |
153
| – | – |
2017 Q4
20 quarters
|
|
|
OBE
6156
Obsidian Energy
OBE
$694M
| $1K | ﹤0.01% |
103
-938
| -90% | -$7.29K |
2022 Q1
3 quarters
|
|
|
IMDX
6157
Insight Molecular Diagnostics
IMDX
$113M
| $1K | ﹤0.01% |
155
-235
| -60% | -$2.59K |
2017 Q4
20 quarters
|
|
6158
Oil-Dri
ODC
$1.3B
| $1K | ﹤0.01% |
+56
| New | +$842 |
2022 Q4
0 quarters
|
|
6159
OP Bancorp
OPBK
$231M
| $1K | ﹤0.01% |
87
| – | – |
2018 Q2
18 quarters
|
|
6160
Oxford Square Capital
OXSQ
$138M
| $1K | ﹤0.01% |
+233
| New | +$710 |
2022 Q4
0 quarters
|
|
6161
Invesco Leisure and Entertainment ETF
PEJ
$363M
| $1K | ﹤0.01% |
+33
| New | +$1.24K |
2022 Q4
0 quarters
|
|
6162
Innovator US Equity Power Buffer ETF May
PMAY
$816M
| $1K | ﹤0.01% |
+22
| New | +$616 |
2022 Q4
0 quarters
|
|
6163
Invesco Global Listed Private Equity ETF
PSP
$213M
| $1K | ﹤0.01% |
31
| – | – |
2020 Q4
8 quarters
|
|
6164
Rapid Micro Biosystems
RPID
$46.1M
| $1K | ﹤0.01% |
1,276
-1,414,867
| -100% | -$3.42M |
2021 Q3
5 quarters
|
|
6165
Cohen & Steers Quality Income Realty Fund
RQI
$1.49B
| $1K | ﹤0.01% |
154
+119
| +340% | +$1.43K |
2022 Q3
1 quarter
|
|
6166
CALL
Sabre
SABR
$795M
| $1K | ﹤0.01% |
+200
| New | +$1.12K |
2022 Q4
0 quarters
|
|
6167
SAB Biotherapeutics
SABS
$271M
| $1K | ﹤0.01% |
88
-175
| -67% | -$1.6K |
2021 Q4
4 quarters
|
|
6168
Sera Prognostics
SERA
$82.4M
| $1K | ﹤0.01% |
959
-1,199
| -56% | -$1.69K |
2021 Q3
5 quarters
|
|
6169
SGHC Ltd
SGHC
$5.72B
| $1K | ﹤0.01% |
+481
| New | +$1.7K |
2022 Q4
0 quarters
|
|
6170
Solid Biosciences
SLDB
$734M
| $1K | ﹤0.01% |
133
-294
| -69% | -$1.93K |
2018 Q1
19 quarters
|
|
|
SNCR
6171
DELISTED
Synchronoss Technologies
SNCR
| $1K | ﹤0.01% |
107
| – | – |
2018 Q4
16 quarters
|
|
6172
Smart Sand
SND
$226M
| $1K | ﹤0.01% |
641
-284
| -31% | -$538 |
2017 Q4
20 quarters
|
|
6173
Xtrackers S&P 500 ESG ETF
SNPE
$2.81B
| $1K | ﹤0.01% |
+20
| New | +$695 |
2022 Q4
0 quarters
|
|
|
FTH
6174
Faeth Therapeutics
FTH
$733M
| $1K | ﹤0.01% |
33
-53
| -62% | -$1.56K |
2021 Q1
7 quarters
|
|
6175
Simplify US Equity PLUS Convexity ETF
SPYC
$82.8M
| $1K | ﹤0.01% |
+45
| New | +$1.17K |
2022 Q4
0 quarters
|
|
Similar funds
JP Morgan Chase's Q4 2022 Portfolio in Review
As of Q4 2022, JP Morgan Chase held 7,423 positions worth $759B, up 8.9% from $696B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
JP Morgan Chase's Q4 2022 filing shows 754 new, 2,939 increased, 2,285 reduced and 593 closed positions. Its largest new stake was Invesco S&P Emerging Markets Low Volatility ETF: 2,344,997 shares worth $54M. The largest sale was Invesco QQQ Trust, an estimated $1.49B.
By sector, the portfolio is most concentrated in Miscellaneous at 27% of assets, down from 28% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q4 2022 buy was Invesco S&P Emerging Markets Low Volatility ETF: 2,344,997 shares worth $54M.
- JP Morgan Chase added most to Vanguard Tax-Exempt Bond Index Fund in Q4 2022, an estimated $2.54B increase.
- JP Morgan Chase's biggest Q4 2022 reduction was Invesco QQQ Trust, cutting an estimated $1.49B.
- JP Morgan Chase fully exited Duke Realty Corp. in Q4 2022, selling an estimated $424M.
- JP Morgan Chase's ten largest holdings make up 16% of its $759B portfolio in Q4 2022.
- JP Morgan Chase opened 754 new positions and closed 593 in Q4 2022.
- JP Morgan Chase's portfolio value rose 8.9% quarter-over-quarter to $759B.
Based on JP Morgan Chase's 13F filing for Q4 2022, filed 13 Feb 2023.